Press Release
October 28, 2022

Landmark Bio Opens State-of-the-Art Full-Spectrum Biomanufacturing Innovation Center

The Private Equity, Life Sciences and Technology teams advised Landmark Bio™ on the opening of its state-of-the-art full-spectrum development and biomanufacturing facility in Watertown, Massachusetts.

The 44,000 square-foot fully integrated development and manufacturing facility includes laboratory space for translational research and early development, process and analytical development and technology innovation. The biomanufacturing area is comprised of eight cleanrooms for cell therapies, genome editing, viral vector, mRNA and lipid nanoparticle production as well as fill and finish and in-house Quality Control (QC) testing. The facility currently has about 60 staff members and will grow to more than 100 people in the coming years.

Landmark Bio, a statutory public benefit limited liability company, or PBLLC, is a collective endeavor launched by leaders from academia, the life sciences industry, and world renowned research hospitals to accelerate the development and industrialization of novel therapeutics. Founding partners include Harvard College, Massachusetts Institute of Technology, Cytiva, FUJIFILM Diosynth Biotechnologies, and Alexandria Real Estate Equities, Inc.

Goodwin has represented Landmark Bio since its inception. The team advising on the opening of the facility was led by James Barrett, Matt Reardon, Lily Wound and included Ed Amer, Monica Kwok and Nicole Fontes.

For additional details on the facility, please read the press release and coverage in The Boston Globe and Boston Business Journal.